当前位置:首页 >财报库 > 报告详情

罗氏Roche Holdings(RHHBY)2024年年度报告「OTC」(英文版)(216页).pdf

上传人: Kell****reet 编号:652445 2025-05-14 216页 8.08MB

下载:

1、Annual Report 2024This picture shows special nerve cells,so-called motor neurons,which are derived from human stem cells.The neurons are guided through tiny,maze-like channels,which helps researchers to understand their growth and connections and to learn about nerve diseases and treatments.Photo:Ja

2、mes Keaney,pRED scientistWe drive innovationIt starts with an idea nurtured by the belief that we can always do better.Propelled by curious minds pursuing scientific excellence and pushing the boundaries of what is possible.An evolution centred around a single anchor innovation.In all our innovation

3、 engines around the world,we foster an environment where our researchers endeavour to shape the future ofhealthcare.In 2024,we proudly opened a new R&D facility in Switzerland.The Roche Innovation Center Basel is equipped with state-of-the-art labs and technology to foster creativity and collaborati

4、on in tackling healthcares biggest challenges and to advance science,so we all have more time with the people we love.Annual Report 2024|Roche 1Immune cells seen in gastrointestinal cancer tissuetheir presence in many solid tumours suggestsan ongoing immune reaction and,therefore,the manipulation of

5、 them for therapeutic purposes represents an exciting future avenue of research.Photo:Miguel Camacho,Marius Harter,IrinejaCubela,pRED scientistsContentsLetters to shareholders 5 Sustainability Report 15 How we contribute 151Corporate Governance 163 Remuneration Report Report 2024|Roche 3These cells

6、are macrophages derived from induced pluripotent stem cells,stained for varioussubcellular structures and used in complexfunctional cellular assays to examine processes such as phagocytosis,migration andcytokine release.Photo:Ramona Schfer,Nadine Dahm,SimonGutbier,pRED scientistsLetters to sharehold

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据Roche 2024年年报的内容,我总结了以下关键点: 1. Roche在2024年实现了7%的销售增长,达到605亿瑞士法郎。核心每股收益增长12%,达到208亿瑞士法郎。 2. 制药部门销售增长8%,达到462亿瑞士法郎。四大增长驱动产品Vabysmo、Phesgo、Ocrevus和Hemlibra的总销售额为169亿瑞士法郎,同比增长33亿瑞士法郎。 3. 诊断部门在2024年也实现了强劲增长,销售增长10%,达到143亿瑞士法郎。 4. Roche在2024年推出了两款新药Itovebi和PiaSky,以及一款持续血糖监测解决方案和一款全自动质谱系统。 5. Roche在2024年还收购了四家公司,并建立了更多的合作伙伴关系。 6. Roche在2024年进一步强化了对可持续发展的承诺,包括在气候保护方面设定了雄心勃勃的目标,并投资了12亿瑞士法郎建设新的研发中心。 7. Roche在2024年还更新了公司范围内的可持续发展战略,并在多个可持续发展优先领域取得了显著进展。
2024年罗氏集团业绩如何? 罗氏在哪些疾病领域取得重要创新? 罗氏如何通过可持续发展创造长期社会和财务价值?
客服
商务合作
小程序
服务号
折叠